CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chugai Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chugai Pharmaceutical Co Ltd
15F, Nihonbashi Mitsui Tower
2-1-1, Nihonbashi-Muro-machi
Phone: +81 332816611p:+81 332816611 CHUO-KU, TKY  103-8324  Japan Ticker: 45194519
This company was Merged or Acquired on 12/13/2011.
This is a Subsidiary, click here for the Parent Company
Business Summary
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director OsamuOkuda 61 3/1/2021 1/1/2014
Senior Executive Officer, Chief Financial Officer, Senior Manager of Finance, Director IwaakiTaniguchi 57 3/28/2024 8/1/2022
Senior Executive Officer, Chief Director of Translational Research, Director HitoshiIikura 54 3/1/2024 4/1/2022
12 additional Officers and Directors records available in full report.

Business Names
Business Name
4519
CHGCY
Chugai Pharmaceutical Co., Ltd.
Chugai U.S.A., Inc.

General Information
Number of Employees: 7,604 (As of 12/31/2023)
Outstanding Shares: 1,645,313,955 (As of 12/31/2023)
Shareholders: 54,361
Stock Exchange: TYO
Fax Number: +81 332812828


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024